Skip to main content

Hoth Therapeutics Stock Forecast, Price & News

+0.03 (+2.21 %)
(As of 05/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume535,128 shs
Average Volume3.68 million shs
Market Capitalization$33.18 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive HOTH News and Ratings via Email

Sign-up to receive the latest news and ratings for Hoth Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Hoth Therapeutics

Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. Its pipeline portfolio includes HT-001, a topical formulation for the treatment of mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy; HT-002 to treat illness associated with SARS-CoV-2 infection; HT-003D for the topical treatment in acne and psoriasis applications; HT-003IB to treat inflammatory bowel diseases; HT-004 for the treatment of asthma, atopic dermatitis, and other allergic diseases; HT-005 Z-PODS to treat cutaneous lupus erythematosus; HT-006 for treatment of multiple bacterial pathogens. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; and the University of Cincinnati. It also has a partnership agreement with Zylö Therapeutics Inc. co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life; and research collaboration agreement with Weill Cornell Medicine to continue the advancement of HT-003 for acne treatment research. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.


See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:HOTH
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Book Value$0.24 per share


Net Income$-7,700,000.00




Market Cap$33.18 million
Next Earnings Date5/19/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

0.46 out of 5 stars

Medical Sector

1706th out of 2,032 stocks

Pharmaceutical Preparations Industry

695th out of 768 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Hoth Therapeutics (NASDAQ:HOTH) Frequently Asked Questions

What stocks does MarketBeat like better than Hoth Therapeutics?

Wall Street analysts have given Hoth Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Hoth Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Hoth Therapeutics?

Hoth Therapeutics saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 896,100 shares, a decrease of 42.2% from the March 31st total of 1,550,000 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ∞ days.
View Hoth Therapeutics' Short Interest

When is Hoth Therapeutics' next earnings date?

Hoth Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 19th 2021.
View our earnings forecast for Hoth Therapeutics

How were Hoth Therapeutics' earnings last quarter?

Hoth Therapeutics, Inc. (NASDAQ:HOTH) announced its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.01.
View Hoth Therapeutics' earnings history

How has Hoth Therapeutics' stock been impacted by Coronavirus?

Hoth Therapeutics' stock was trading at $3.84 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HOTH stock has decreased by 63.8% and is now trading at $1.39.
View which stocks have been most impacted by COVID-19

Who are Hoth Therapeutics' key executives?

Hoth Therapeutics' management team includes the following people:
  • Mr. Robb Knie, Pres, CEO & Chairman (Age 52, Pay $525k)
  • Ms. Jane H. Springer, VP of Operations (Age 36, Pay $215k)
  • Mr. David S. Briones, Chief Financial Officer (Age 45)
  • Dr. Stefanie Johns Ph.D., Chief Scientific Officer (Age 36)

Who are some of Hoth Therapeutics' key competitors?

What other stocks do shareholders of Hoth Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Citius Pharmaceuticals (CTXR), Ocugen (OCGN), Fulcrum Therapeutics (FULC), Heat Biologics (HTBX), Tonix Pharmaceuticals (TNXP), AIM ImmunoTech (AIM), Aytu Biopharma (AYTU), Gilead Sciences (GILD), iBio (IBIO) and Nabriva Therapeutics (NBRV).

When did Hoth Therapeutics IPO?

(HOTH) raised $8 million in an initial public offering (IPO) on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

What is Hoth Therapeutics' stock symbol?

Hoth Therapeutics trades on the NASDAQ under the ticker symbol "HOTH."

Who are Hoth Therapeutics' major shareholders?

Hoth Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (9.51%), Renaissance Technologies LLC (0.93%), Bank of New York Mellon Corp (0.11%), BlackRock Inc. (0.11%) and XTX Topco Ltd (0.05%).
View institutional ownership trends for Hoth Therapeutics

Which major investors are selling Hoth Therapeutics stock?

HOTH stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc..
View insider buying and selling activity for Hoth Therapeutics
or view top insider-selling stocks.

Which major investors are buying Hoth Therapeutics stock?

HOTH stock was bought by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Renaissance Technologies LLC, Bank of New York Mellon Corp, and XTX Topco Ltd.
View insider buying and selling activity for Hoth Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Hoth Therapeutics?

Shares of HOTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hoth Therapeutics' stock price today?

One share of HOTH stock can currently be purchased for approximately $1.39.

How much money does Hoth Therapeutics make?

Hoth Therapeutics has a market capitalization of $33.18 million.

How many employees does Hoth Therapeutics have?

Hoth Therapeutics employs 3 workers across the globe.

What is Hoth Therapeutics' official website?

The official website for Hoth Therapeutics is

Where are Hoth Therapeutics' headquarters?

Hoth Therapeutics is headquartered at 1 Rockefeller Plaza Suite 1039, New York NY, 10020.

How can I contact Hoth Therapeutics?

Hoth Therapeutics' mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The company can be reached via phone at 646-756-2997 or via email at [email protected]

This page was last updated on 5/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.